Whele LLC Announces National Voluntary Recall of Mighty Bliss Electric Heating Pad Due to Product Safety Concerns
BOSTON, Oct. 24, 2022 /PRNewswire/ -- Whele LLC, of Boston, MA, is voluntarily recalling its Mighty Bliss Electric Heating Pad, due to product safety concerns. Use of this product may lead to burns, mild shocks, or rashes/irritation.
This recall applies to 544,212 Mighty Bliss Electric Heating Pad units manufactured between 08JAN21 to 03JAN22 and distributed from 29JUL21 through 21JUL22. Product was sold via Amazon.com and Walmart.com.
Model Numbers and Descriptions Below:
MB-001 (NA-H1121B): Large (12" x 24") Blue Electric Heating Pad
MB-002 (NA-H21C): Extra-Large (20" x 24") Blue Electric Heating Pad
PE-MtyBls-HeatPad-12x24-Gry-V2(NA-H1121B): Large (12" x 24") Grey Electric Heating Pad
Affected Product Lots
The product lot number can be found directly on the heating pad listed in black text beneath the product instructions.
This recall has been initiated due to product safety concerns. We received 286 complaints between July 2021 to September 2022 related to the product overheating, sparking, burning, or presenting other electrical problems. 31 of these complaints reported injuries such as mild shocks, burns, and rashes or irritation.
Risk to Health
Use of this product may lead to electric shocks and/or skin irritation, rashes, blisters, or burns. Severe burns may result in infection or formation of scar tissue.
Actions to be taken by the Customer/User
Immediately cease use of the product.
If you have product on hand, please take the following actions: a. Ensure unit is unplugged. b. Safely cut the cord off the device c. Take a picture of the device to demonstrate that the device can no longer be used d. Upload a picture of the device with the cord cut to our website
Immediately examine your inventory and quarantine the product subject to recall. We will be in contact to gather any remaining inventory for destruction.
If you may have further distributed this product, please identify your customers and notify them within two (2) business days of this product recall. Your notification to your customers may be enhanced by including a copy of this recall notification and must include the following url: www.mightyblissheatingpadrecall.expertinquiry.com
Consumers with questions can call 866-918-8768, Monday through Friday from 8am to 5pm EST.
This recall is being made with the knowledge of the Food and Drug Administration.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
About Whele LLC
Whele LLC is a leading consumer goods company that sells products on Amazon and other third party marketplaces. To learn more about Mighty Bliss, one of Whele's brands, visit: https://www.mightybliss.com/
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...
YOUR LEGAL RIGHTS MAY BE AFFECTED
There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...